LABT
Healthcare BiotechnologyLakewood-Amedex Biotherapeutics, Inc.
$0.93
+0.01 +0.69% today
Price History
Not enough data
Key Stats
Market Cap
2.20M
Avg Volume
2.37M
EPS
-$3.22
52W High
$98.20
52W Low
$0.91
Div. Yield
0.0%
Valuation
P/B Ratio
0.47
EV/EBITDA
0.31
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(402.8%)
Return on Assets
(139.4%)
Liquidity & Leverage
Current Ratio
7.70
Quick Ratio
7.29
Debt / Equity
0.02
Total Cash
4.58M
Total Debt
101,619
About
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
lakewoodamedex.com